A Holistic Approach to Hair Loss Treatment: How Evolution Hair Loss Institute Combines Hormonal, Nutritional, and Inflammatory Factors to Restore Hair and Health

Hormonal

Hormonal causes of hair loss (Section 4) involve a sensitivity to dihydrotestosterone (DHT), a potent androgen derived from testosterone. While this type of hair loss is mediated by a hormone (DHT), the propensity to the effects of DHT is influenced by both genetic and epigenetic factors. This genetically influenced, hormone mediated type of hair loss is called androgenetic alopecia (AGA). AGA is also known as patterned hair loss: male pattern or female pattern hair loss.

Since the conversion of testosterone to DHT is facilitated by the activity of the 5-α reductase (5- AR) enzyme, many treatments for hormonal hair loss target this pathway. Finasteride and dutasteride are the leading treatments for AGA and focus on 5-AR inhibition. Minoxidil is also commonly used to treat AGA. However, oral 5-AR treatments have been flagged to lead to adverse health effects, including PFS, changes in reproductive health, and depression.

Natural remedies such as saw palmetto, pumpkin seed, and pygeum extract may be promising treatments, as initial findings suggest effective hair growth with minimal to no side effects. Further research and clinical trials are needed to fully assess the efficacy and long-term outcomes for these natural remedies to DHT-related hair loss.

Nutritional

This paper reviews the connection between vitamin and mineral deficiencies and hair loss, introducing the concept of “nutritional alopecia.” These deficiencies may contribute to diffuse hair thinning or increase the propensity for androgenetic alopecia.

Section 5 focuses on vitamins D and B, iron, ferritin, and zinc. Vitamin D deficiency has been associated with various hair loss conditions. However, evidence regarding the efficacy of supplementation remains inconclusive, necessitating further research, especially for FPHL and TE. Similarly, while vitamins B12 and folate are crucial for hair follicle turnover, their direct link to hair loss remains uncertain.

Iron and ferritin deficiencies have been observed among individuals experiencing hair loss, particularly in women, emphasizing the need for monitoring and addressing these deficiencies in hair loss management. Zinc’s role in hair follicle cycling is noted, with mixed research findings regarding its deficiency in hair loss, urging further investigation into the potential benefits of zinc supplementation.

Inflammatory

The inflammatory factor is perhaps the broadest of the factors detailed in this paper (Section 6). Hair loss can occur as a result of inflammation from various conditions such as autoimmune disease (e.g., lupus, alopecia areata [AA], etc.), endocrine disorders, metabolic conditions, gut dysbiosis, or drug toxicity.

Inflammatory hair loss can present as patchy hair loss, as seen in conditions such as seborrheic dermatitis or psoriasis. A common type of inflammatory hair loss is AA, an autoimmune disorder leading to non-scarring alopecia. Scarring alopecia, also known as cicatricial alopecia, refers to a group of hair loss disorders where inflammation damages and destroys hair follicles, leading to irreversible hair loss.

Gut dysbiosis—including small intestinal bacterial overgrowth (SIBO)— is linked to disruptions in the gut microbiome. It is associated with AA and possibly androgenetic alopecia (AGA), suggesting a potential role for both pre- and probiotics in hair growth, though further research is needed.

Drug toxicity, particularly from medications like statins and bupropion, can induce inflammation leading to hair loss. Additionally, there may be an influence of blood type on disease susceptibility.

Growth Stimulants

Growth stimulants work through various mechanisms: increasing the anagen phase, increasing blood flow to the scalp, increasing growth factor availability, or creating a more favorable environment for hair growth.

Growth stimulant therapies investigated are LLLT, PRP, exosomes, peptides, and microneedling (Section 7). Each of these options are promising in terms of promoting hair growth with minimal side effects, potentially offering safe and effective treatments in the future. However, their effectiveness is limited until the underlying cause of hair loss is addressed.

Common Gaps in the Research

Vitamin and mineral supplementation for treating hair loss requires more large-scale, longitudinal research and clinical trials. While a correlation seems to be present, the link between gut microbiome, dysbiosis, and hair loss also needs further investigation. Moreover, previous literature stresses the need to distinguish between male pattern hair loss (MPHL) and female pattern hair loss (FPHL) to create more customized treatments. Finally, more research is needed to elucidate how promising growth stimulants promote hair growth (Section 8).

Conclusion

The Gaunitz Trichology Methodology (GTM) is a novel and personalized approach to hair loss. Based on 22 years of clinical experience, the GTM divides hair loss into three categories: hormonal, nutritional, and inflammatory. This distinction is crucial not only for diagnosis, but also for the effective management of hair loss.

The GTM offers a holistic and customized treatment plan for each patient, unlike conventional treatments that often adopt a one-size-fits-all approach. The GTM also integrates natural remedies and dietary support to enhance the effectiveness and safety of traditional treatments, which have limitations and potential side effects.

This approach highlights the importance of individualized medical care, acknowledging that each patient has unique needs and responses based on their genetic makeup, lifestyle factors, and overall health profile. As the knowledge of hair loss advances, personalized approaches like the GTM may lead to more successful hair growth treatments that result in better outcomes, fewer side effects, and higher patient satisfaction.

Section 1: Abbreviations Used

The following are common abbreviations that will be used throughout this white paper:

Table 1. Common abbreviations.

Section 2: Background

Hair loss, medically referred to as alopecia, is a common condition experienced by a large portion of the general population. Alopecia can occur due to a wide range of causes and circumstances, including hormones, stress, autoimmune response, diet, medications, and infection . Androgenetic alopecia (AGA), or patterned baldness, is the most common type of hair loss and affects at least 80 percent of men¹ and 50 percent of women in their lifetimes². Alopecia areata, a type of alopecia that stems from an autoimmune disease, affects approximately 2 percent of the general population in their lifetime³.

Hair loss in any form has the potential to impact an individual’s quality of life, as people place an importance on hair and social life, security, and self-confidence⁴.

While there are established treatments for hair loss such as minoxidil and finasteride, it can be difficult to select the best treatment for a patient due to the wide variety of options and the lack of standardization in clinical studies investigating these treatments. Additionally, without properly identifying the cause of hair loss, these treatments may be ineffective and even lead to more hair loss for some individuals.

Differences in hair loss causes, symptom presentation, and patient preference further complicates the decision of treatment for each patient,1 as approved treatments tend to only treat one factor involved in hair loss, such as blocking dihydrotestosterone (DHT). Most conventional treatments for hair loss are limited, ineffective, or have undesirable side effects.

To mitigate this, personalized medicine and nutrition can be beneficial by increasing the likelihood of successful treatment, reducing the possibility for side effects, and improving patient satisfaction and adherence to treatment⁵.

The Gaunitz Trichology Methodology (GTM) was created by William Gaunitz, FWTS, the Founder of Evolution Hair Loss Institute and Advanced Trichology Products to address hair loss using a holistic, individualized approach. Rather than using a “one-size-fits-all” treatment, patients receive hair loss treatment that is tailored to their specific needs. The first step in this process is to determine the underlying cause of hair loss: hormonal, nutritional, inflammatory, or a combination thereof Understanding the cause of hair loss in each individual guides this therapeutic approach. Many of the treatments in the GTM are covered in this paper.

The purpose of this paper is to show how the GTM can effectively treat hair loss and outperform other conventional methods. The GTM is based on the premise that hair loss has three main causes: hormonal, nutritional, and inflammatory. This distinction is not only for diagnostic purposes, but also for management. The goal of therapy is to effectively address the underlying cause leading to a patient’s hair loss.

This paper will present evidence on how the GTM holistically considers each of these causes, explaining how they interact with each other—sometimes in complex, bidirectional relationships—to achieve hair regrowth.

The paper is organized as follows:

Section 4 examines the hormonal aspect of hair loss and the treatments that can balance it.

Section 5 explores the nutritional aspect and the latest research on dietary supplements.

Section 6 analyzes the inflammatory aspect and the factors that contribute to it.

Section 7 discusses other hair growth stimulants and their role in enhancing hair restoration.

Let us now dive into the Gaunitz Trichology Method and see how it works.

Section 3: The Role of Androgens in Hair Loss and the GTM Approach

There are many factors that can cause hair loss, such as genetics, stress, and aging, but androgens play a crucial role as mediators for each of these factors. Hormones are chemical messengers that regulate various bodily functions, including hair growth cycles.

As considered in the GTM approach, hormonal hair loss involves a sensitivity to an excess of dihydrotestosterone (DHT), a potent androgen derived from testosterone. The propensity to the effects of DHT is influenced by both genetic and epigenetic factors. In this section, we will explore how sensitivity to DHT determines hair loss, and what you can do to prevent and treat it. We will also review the leading treatments for hormonal hair loss, both conventional and natural, and explain how they fit into the GTM.

This genetically influenced, hormone mediated type of hair loss is called androgenetic alopecia (AGA). This will be the focus of this section.

Androgenetic Alopecia

Definition and Pathogenesis

Androgenetic alopecia (AGA), also known as male pattern hair loss (MPHL) in males and female pattern hair loss (FPHL) in females⁶, is the most common type of patterned alopecia in both men and women⁷. The main culprit in this type of alopecia is a genetic sensitivity to the androgen DHT, which can show up in a person’s life at a certain time or due to changes in gene expression. Compared to testosterone, DHT is more potent and has a much greater affinity for the androgen receptor in people whose hair follicles are genetically more sensitive to DHT⁶. Another important factor in the hormonal cascade leading to hair loss is the 5-alpha reductase enzyme (5-AR), which is responsible for converting testosterone to DHT⁷. Those without a genetic sensitivity to DHT do not experience hair loss related to androgens..

As a result of this genetic predisposition to DHT or excessive 5-AR activity, hair follicles experience progressive miniaturization, leading to thinner, less visible hair in the affected area⁸. AGA primarily involves the top of the scalp, but it can also affect the temples and less frequently, the temporal points. This type of hair loss progresses uniformly and slowly, often taking years to become visibly noticeable.

It is important to note that AGA involves a genetic predisposition to increased production and activity of androgens and androgen receptors⁶. To demonstrate this, we will discuss a few studies that highlight the role of DHT and 5-AR in hormone-related hair loss.

Genetic Factors

A 1974 study examined people with genetic mutations that affected the expression of the type 2 5-AR enzyme¹¹. The male subjects had reduced DHT production, normal levels of testosterone, but sparse facial and bodily hair. The female subjects did not appear to have sparse hair despite having the same genetic mutation as the male subjects, indicating that the connection between DHT, 5-AR, and FPHL may be explained by other factors, such as the androgen-estrogen ratio.

A series of studies by Hamilton investigated male pattern hair loss among eunuchs—males who have been castrated for various reasons⁹. Those who were castrated prior to puberty appeared to maintain a juvenile hairline while those who were castrated after puberty exhibited hairlines more consistent with the general population. None of Hamilton’s subjects experienced progressive hair loss one year into the study. Moreover, when Hamilton administered testosterone to the castrated men, only those with a family history of MPHL developed pattern hair loss.

A separate study found that plucked hair follicles and scalp skin samples from balding subjects contained a higher level of DHT compared to the follicles and skin from non-balding subjects.6 Twin studies have also demonstrated that finasteride6 and dutasteride¹⁰, two drugs that block the 5-AR enzyme, were more effective than placebo in slowing down hair loss among twins predisposed to MPHL. This evidence indicates that DHT is a key factor in the onset and progression of AGA, and that inhibiting the 5-AR enzyme can help to prevent and treat it.

Management

To understand how AGA is treated under the Gaunitz methodology, we will begin by explaining that 5-AR has two different forms: type 1 and type 2⁶. Type 2 5-AR is responsible for a majority of DHT conversion. Currently, the main focus for AGA treatment is 5-AR inhibition with finasteride and dutasteride being the primary 5-ARIs (5-AR inhibitors) on the market today⁷.

While agents such as minoxidil can be paired with finasteride to enhance hair growth results⁸ it is important to note that minoxidil is a growth stimulant and does not address the hormonal component of hair loss.

Natural remedies, such as pumpkin seed, saw palmetto, and pyguem have been tested as potential treatments for AGA. These natural remedies have shown clinical improvement in hair growth without negative side effects and are easily accessible.

Finally, while the pathogenesis of AGA in males is well-studied, the pathogenesis of AGA in females is not fully understood. Clinical trials testing finasteride revealed that patterned hair loss in females may differ from that in males⁶. There also exists a lack of longitudinal studies, especially studies lasting longer than one year, that focus on FPHL rather than MPHL.

Current clinical research tends to imply that successful treatments for male AGA may also work for FPHL. While FPHL has been treated before using a wide range of therapeutic agents, previous analyses have found only topical minoxidil to be effective for FPHL⁴. Minoxidil will be discussed in more detail in Section 6: Growth Stimulants.

Estrogen may serve as a protective factor against hair loss, as shown by the increase in female pattern hair loss after menopause, longer hair growth during pregnancy, hair loss in women taking certain breast cancer medications, and full hair regrowth in transgender individuals with androgenetic alopecia who take estrogen¹². Estrogens can promote hair growth by extending the anagen phase, which is the active growth stage of the hair cycle. They do this by influencing the conversion of androgens, such as DHT, to estrogens and boosting growth factors that help hair cells multiply¹³. GTM theorizes that FPHL is the same action as male, but the estrogen protection changes the pattern and hair loss rate.

The following subsections will discuss each therapy that can be included in the GTM and how they target the hormonal component of hair loss.

Finasteride

Finasteride is a 5-ARI that specifically targets type 2 5-AR. Its primary indication is for benign prostate hyperplasia, but is often used to treat DHT-related hair loss such as AGA. Finasteride is available in oral and topical formulations. Currently, the Food and Drug Administration (FDA) has only approved oral finasteride for the treatment of MPHL along with topical minoxidil⁸. Only topical minoxidil is approved for FPHL⁸, but oral finasteride has been used off-label to treat FPHL². A double-blind, randomized clinical trial compared the efficacy of topical and oral forms of finasteride and both treatment groups saw hair growth after six months of daily treatment. However, there was no statistically significant difference in hair regrowth effectiveness between these two routes of administration¹¹.

Post-finasteride syndrome (PFS) is a term used to describe the side effects that some individuals experience after discontinuing use of oral finasteride. PFS can affect various aspects of health, such as:

Reproductive health: Loss of libido, erectile dysfunction, fertility issues.

Brain function: Changes in neuroactive steroids, decreased neurogenesis.

Behavioral health: Depression, suicide.

Kidney function: Apoptosis of kidney cells, fibrosis, lymphocyte infiltration.

Liver function: Changes in neuroactive steroids that may result in hyperinsulinemia and hepatic steatosis.

Vision: Dry eye disease.

The wide range of side effects may be related to the presence of 5-AR type 1 and 2 in many tissues throughout the body and finasteride’s ability to reduce levels of neuroactive steroids (such as pregnenolone, progesterone, and estradiol) in addition to inhibiting the conversion of testosterone to DHT. Finasteride has also been found to reduce dopamine levels and inhibit dopamine signaling¹². Additionally, gut microbiome changes were observed in patients suffering from PFS¹³. These side effects have been observed primarily in men. However, other studies have found a lack of association between men being treated with finasteride for androgenetic alopecia and an increased risk of sexual dysfunction¹⁴.

A study of healthy women showed that prolonged use of oral finasteride can improve hair growth. Despite the recorded success, use of finasteride was also associated with adverse side effects such as irregular menstrual cycles, aromatase disorder, high cholesterol, heavy menstrual bleeding, and induced DNA damage. In fact, this study recommends that finasteride should not be used to treat androgenetic alopecia in women¹⁵. Further studies are needed to both determine the pathogenesis of FPHL and prolonged use of finasteride as a treatment option.

A topical formulation of finasteride is being considered as an alternative to oral finasteride, given the adverse side effects observed with prolonged oral use. A recent systematic review of topical finasteride has concluded that it may promote hair growth, according to clinical studies. Additionally, side effects of topical finasteride are generally mild and mainly affect the application site. Side effects for topical finasteride may include site irritation, burning sensation, contact dermatitis, scalp pruritus, and erythema. Topical finasteride is currently not FDA approved, but clinical studies offer promising evidence that it can reduce the adverse effects of oral finasteride¹¹.

Dutasteride

Another option for the treatment for DHT-related hair loss is dutasteride, a drug with the same mechanism of action as finasteride—5-AR inhibition. However, dutasteride inhibits both type 1 and type 2 isoenzymes for 5-AR whereas finasteride only inhibits type 2 ²,⁷. Additionally, dutasteride is 100 times more potent at inhibiting type 2 5-AR than finasteride² and the half-life of dutasteride is much longer than that of finasteride ⁷,¹⁶.

Studies have found dutasteride to yield better results than finasteride ⁷,¹⁶ and minoxidil in terms of hair growth. In the United States, dutasteride has not been FDA approved for AGA treatment; however, oral dutasteride has been approved by regulators in Japan and South Korea ¹⁹. Observed side effects of dutasteride are similar to that of finasteride¹⁷, though some studies have found a lack of association between dutasteride and sexual dysfunction¹⁸.

Additional studies are needed to determine the association between dutasteride and PFS-like side effects, though its long half-life may influence any associations found.

Natural Remedies

Natural remedies such as saw palmetto, pumpkin seed, pyguem, and green tea can offer valid options for managing androgenetic alopecia and DHT-related hair loss. Their effectiveness in hair loss may be related to their anti-inflammatory and anti-androgenic properties. Natural remedies are also safer and more tolerable than more toxic treatments such as finasteride and dutasteride. While several of these natural remedies are still under investigation, the current literature suggests that they can be useful additions or alternatives to drug treatments.

Saw Palmetto

Saw palmetto (SP) is a supplement derived from the Serenoa repens dwarf trees of North America. SP oil is rich in fatty acids (namely, lauric acid, myristic acid, and oleic acid) that have been found to inhibit the 5-AR enzyme and restrict the conversion of testosterone to DHT in the oral formulation ²⁰,²¹, similar to finasteride and dutasteride. SP supplements are available in capsule form and SP is included as a key ingredient in shampoos and conditioners formulated to address hair loss²¹. Previous research suggests that saw palmetto can be used as a valid treatment for mild to moderate AGA with no side effects²², though other studies have yielded ambiguous results. Still, SP remains a safe and effective alternative to drug treatment.

Pumpkin Seed

Widely cultivated in Central and South America and Asia, pumpkin seed is reported to be a 5- AR inhibitor, similar to saw palmetto. Pumpkin seed is available as a supplement in capsule form²¹. Originally, pumpkin seed was found to be an effective treatment for patients with benign prostatic hyperplasia due to the phytosterols present in pumpkin seed oil²³. Pumpkin seed oil also contains lipids that may help treat AGA, alone or combined with saw palmetto²¹. A randomized control trial found that use of pumpkin seed supplement for 24 weeks was effective in achieving hair growth for male subjects with AGA. Additionally, subjects were satisfied with hair growth improvement and the vast majority reported no adverse symptoms²³.

Green Tea

Green tea is a beverage commonly consumed around the world and is derived from the leaves of Camellia sinensis²⁴. Green tea is known for its antioxidant content and has also been evaluated as a natural treatment for hair loss. Its beneficial properties are related to the presence of epigallocatechin gallate (EGCG). EGCG has been found to have anti-inflammatory and stress reducing effects, influencing hair regrowth in mice²⁵. Additionally, EGCG stimulates hair growth due to its proliferative and antiapoptotic effect on dermal papilla cells²⁶. These effects also inhibit type 1 5-AR activity. Other health benefits of green tea include anti-carcinogenic activity, antiviral and anti-allergic potentials, antibacterial activity, improved insulin sensitivity, reduced risk of obesity, among other effects, which may further reduce the risk of hair loss as a result of illness or inflammation²⁷.

Pygeum Extract

Pygeum extract is a naturally occurring substance from the dried bark of the Pygeum africanum tree. It contains triterpenes and phytosterols that have shown to have 5-AR inhibitory properties. In a clinical study of post-menopausal women with AGA, a lipid co-extract of saw palmetto and pygeum was found to be an effective and safe treatment for AGA. Results showed an increase of anagen hairs and a decrease of telogen hairs among the study subjects and with minimal side effects. Moreover, this natural remedy containing pygeum extract was concluded to be a well- tolerated treatment for AGA in post-menopausal women, as other pharmaceutical treatments such as finasteride and dutasteride are contraindicated for this population²⁸.

Stinging Nettle Extract

Also known as Urtica dioica, stinging nettle extract has also shown to have 5-AR inhibitory, antioxidant, and anti-inflammatory properties. ß-sitosterol, in particular, is a component of stinging nettle extract. This compound could stimulate hair growth by increasing the activity of enzymes like catalase and glutathione, thereby reducing oxidative stress on the scalp ²⁹. A combination of herbal extracts formulated in an herbal shampoo, in which stinging nettle was a key ingredient, was found to help prevent scalp from falling out and reducing hair loss in a clinical study³⁰.

Topical Melatonin

Melatonin is a neurohormone known for its high potential for antioxidant activity, regulating biorhythms, sleep cycles, and influences the aging process. It can combat the oxidative stress that is associated with AGA and general hair loss. While the specific mechanism of action of melatonin regarding hair growth is under consideration, it is theorized that melatonin may interact with androgens and estrogen and their receptors.

A collection of studies have demonstrated the positive effects of topical melatonin on hair growth, including a randomized control trial. Melatonin could be a well-tolerated and effective treatment option for both men and women experiencing early-stage AGA and can serve as a potential alternative to other treatments such as minoxidil and finasteride³¹.

Table 2. Common treatments for androgenetic alopecia.

Section 4: How Nutritional Factors Affect Hair Loss and Growth

This paper reviews the connection between vitamin and mineral deficiencies and hair loss, introducing the concept of “nutritional alopecia.” These deficiencies may contribute to diffuse hair thinning or increase the propensity for androgenetic alopecia.

Vitamin supplementation has been considered as an effective treatment for nutritional hair loss. While there is a growing body of evidence that demonstrates that hair loss is associated with each of the mentioned nutritional deficiencies in this section, further research is needed to confirm the efficacy of nutritional supplementation in treating hair loss. As additional studies are ongoing, addressing the nutritional aspect of hair loss has become more important as is the understanding that current treatment regimens may not be the only avenues for hair loss management³².

The GTM is cognizant of this burgeoning area of hair loss treatment and has included nutritional supplementation as part of their methodology in response. This section will cover prominent vitamins and minerals and their connection to hair loss: vitamin D, vitamin B, folate, iron, ferritin, zinc, and lysine. Additionally, this section will briefly cover the GTM’s incorporation of blood type into their treatment for nutritional factors of hair loss.

Vitamin D

Vitamin D is a fat-soluble vitamin that can be obtained through diet and ultraviolet radiation. It is an essential vitamin because it regulates a plethora of bodily processes and possesses anti- inflammatory properties ³³. For example, vitamin D is responsible for the differentiation and growth of hair follicle keratinocytes³⁴. Low levels of vitamin D have been reported in several autoimmune diseases, indicating an immunoregulatory role in the human body³⁵. It is estimated that 50 percent of the world’s population is vitamin D deficient³⁶. Additionally, vegetarian and vegan diets have been found to lead to vitamin D deficiencies ³⁷.

Several studies have found low levels of vitamin D to be associated with AGA, TE³⁸, and AA. Reversing gut dysbiosis is also theorized to aid in the absorption of nutrients required for hair growth, including vitamin D³⁹. In a retrospective study, Tamer et al. observed significantly low serum vitamin D levels among patients complaining of hair loss⁴⁰. Promising evidence of the efficacy and safety of a treatment regimen involving topical vitamin D3, bimatoprost, and microneedling for AA was found by Ali et al⁴¹.

However, there is a lack of conclusive evidence that vitamin D supplementation aids in the treatment of hair loss. Further studies are needed to determine the efficacy of vitamin D supplementation for the management of hair loss on a large scale while controlling for confounding factors such as environment, stress, nutrition, and sun exposure⁴². Additionally, we need more research specifically examining the role of vitamin D treatment for FPHL and TE⁴³.

Vitamin B and Folate

Vitamin B includes a total of eight water-soluble vitamins, but only riboflavin (B2), biotin (B7) folate (B9) and B12 have been examined for a potential connection to hair loss⁴⁴. Vitamin B12 and folate both are considered important for the turnover of hair follicle cells⁴⁵.

However, the connection between vitamin B and hair loss remains unclear. Vegetarianism and veganism have been found to lead to vitamin B12 deficiency if not properly supplemented ⁴⁶. Deficiency in vitamin B12 can potentially decrease hemoglobin levels, which can indirectly impact the severity of TE⁴⁷. A separate study retrospectively observed lower vitamin B levels in only a few patients with hair loss⁴⁸.

There is a lack of sufficient evidence between vitamin B12 and folate deficiencies and hair loss⁴⁹. A study performed on mice found that gut dysbiosis, when paired with a biotin-deficient diet, lead to the development of alopecia⁵⁰. The current literature generally does not suggest biotin supplementation to treat hair loss⁵¹.

Iron

Iron is an important mineral that plays an essential role in the proper functioning of many bodily processes. Iron deficiency is the most common nutritional deficiencies in the world³⁰ and can lead to chronic inflammatory conditions³¹.

Past research examining iron deficiency and hair loss have yielded mixed results. Deficiency in iron can potentially decrease hemoglobin levels, which can indirectly impact the severity of TE⁵². A 2006 review states that there is insufficient evidence to recommend universal screening for iron deficiency among patients experiencing hair loss⁵³. Most research examining iron deficiency and hair loss focuses on women exclusively though there are studies that show that vegans and vegetarians may be at greater risk of iron deficiency⁵⁴.

Ferritin

Serum ferritin is a protein that is needed to successfully store iron¹⁰. Early detection of iron deficiency can be accomplished by examining serum ferritin levels⁵⁵. Additionally, ferritin has been used as an indicator for hair loss in previous research²⁴. However, there is debate on using serum ferritin levels as an indicator of iron deficiency anemia, as serum ferritin can also be used as a marker for inflammatory diseases⁵⁶.

A retrospective study by Tamer et al. found that ferritin levels were significantly lower in patients complaining of hair loss⁵⁷. Park et al. observed in a retrospective study that patients with FPHL and were premenopausal had significantly lower serum ferritin levels than their matched controls. The serum ferritin levels were not statistically significantly different between FPHL patients and their control counterparts who were post-menopausal³². Iron deficiency and serum ferritin levels are often documented among women experiencing hair loss⁵⁸. In the past, the association between iron deficiency, ferritin levels, and men experiencing hair loss has not been clear due to a lack of research inclusive of MPHL patients⁵⁹. Lower serum ferritin levels were found in vegans in comparison to non-vegans⁶⁰.

Zinc

Zinc is essential for protein and nucleic acid synthesis as well as metabolic processes⁶¹. It plays an important role in hair follicle cycling along with copper³³. Zinc is considered a trace element, meaning that zinc can only be supplied to the body through diet and nutrition⁶². In fact, zinc is more easily absorbed when consumed via animal products compared to plant products, leading to vegetarianism and veganism to be linked to zinc deficiency ⁶³,³⁸. Zinc deficiency is a key pathogenic element in acrodermatitis enteropathica, with one of the symptoms being alopecia⁶⁴.

Previous research has yielded mixed results regarding the relationship between zinc deficiency and hair loss. Low zinc levels were found in only a few patients with hair loss in retrospective study conducted in 2020²⁷. Kil et al. found in their study that zinc levels were significantly lower among patients with AGA, TE, and AA, though further studies should be conducted to determine the efficacy of zinc supplementation for treating hair loss⁶⁵.

Lysine

L-lysine is an essential amino acid in the hair root that is responsible for hair shape and volume⁴⁰. L-lysine can be consumed through meat, fish, and eggs⁶⁶. There is evidence that supplementation of L-lysine can improve zinc and iron absorption⁴¹, which can help enable an environment conducive to hair growth. In one study, iron supplementation paired with L-lysine supplementation resulted in a significant increase in the mean serum ferritin concentration⁶⁷.

Conclusion

The GTM posits that by addressing all nutritional aspects of plausible nutritional alopecia through the optimization of blood levels via nutritional supplementation, the outcomes for various hair loss treatments can be significantly enhanced.

According to William Gaunitz’s clinical experience, this approach is particularly effective in stubborn cases of non-responsive male and female pattern hair loss, diffuse unpatterned alopecia (DUPA), and general diffuse thinning throughout the scalp. By ensuring that the body receives the necessary nutrients to support hair health, the GTM theorizes that the efficacy of hair loss treatments is dramatically improved, leading to better overall results for individuals suffering from different types of hair loss.

Section 5: Inflammatory Hair Loss: The Immune Response and Therapeutic Approaches

This paper explores the unified role of immune response in inflammatory hair loss. Current research suggests that inflammatory hair loss conditions—including autoimmune, microbial, and toxin-induced forms—are interlinked by common immunologic responses. These conditions trigger inflammation that weakens hair follicles, leading to hair loss. Inflammatory hair loss is often associated with disruptions in gut health, scalp microbiome imbalances, and systemic inflammatory states.

Treatment strategies addressing underlying immune dysregulation may be most effective in managing these forms of hair loss. This paper discusses therapeutic interventions aimed at mitigating the immune response and restoring homeostasis.

Overview of Inflammatory Hair Loss

Inflammatory hair loss arises from the body’s immune response to various triggers, resulting in damage to hair follicles and surrounding tissue. While inflammatory responses are part of the body’s natural defense, persistent or excessive inflammation can lead to hair follicle damage, stunted growth cycles, and potential scarring. Key drivers of inflammatory hair loss include gut dysbiosis, autoimmune conditions, nutritional deficiencies, microbial scalp infections, and overactive immune responses to environmental or physiological stressors ⁶⁸.

Mechanisms of Inflammatory Hair Loss

1. Immune Response and Autoimmunity

In cases such as alopecia areata (AA), autoimmune processes target hair follicles, leading to an overactive immune response that misidentifies follicle cells as foreign. Immune cells, especially T lymphocytes, attack these structures, causing non-scarring hair loss. The genetic predisposition toward autoimmunity suggests that some individuals are more susceptible to inflammation-based hair loss.

Table 3 presents the different types of alopecia areata.

Table 3. Types of alopecia areata (as defined by the National Alopecia Areata Foundation)⁴⁸

2. Gut Dysbiosis and Microbial Influence

Disruptions in gut microbiome balance (dysbiosis) can lead to systemic inflammation affecting hair growth. An imbalanced gut microbiome can compromise the mucosal barrier, potentially triggering autoimmune and inflammatory responses. Conditions like small intestinal bacterial overgrowth (SIBO) and other gut dysbiosis-related diseases show correlations with AA and may indirectly impact other inflammatory hair loss conditions. Preliminary research indicates that pre- and probiotics can help restore gut health, reducing inflammatory markers.

3. Scalp Microbiome and Microbial Infections

Imbalances in the scalp microbiome—such as fungal overgrowth or bacterial infections—are implicated in conditions like seborrheic dermatitis and folliculitis. These microbial imbalances elicit an immune response that can lead to hair loss if not adequately managed. In cases where the scalp microbiome is disrupted, antifungal and antimicrobial treatments can alleviate inflammation and help restore healthy scalp conditions⁶⁹.

Symptoms of these conditions include scaling, erythema, and pruritus, which can lead to inflammation and subsequent hair loss if left untreated.

Seborrheic dermatitis and dandruff

The exact cause of seborrheic dermatitis is not known. However, colonization of the scalp by fungi plays a role in its pathogenesis⁵⁶.

Dandruff is the mildest and most common form of scalp seborrheic dermatitis, also called pityriasis sicca. This condition is characterized by fine, white, diffuse scaliness on the scalp without underlying erythema. Dandruff may be asymptomatic or accompanied by mild itching⁶⁴.

In its more severe forms, scalp seborrheic dermatitis presents with visible inflammation. These severe variants include pityriasis steatoides, characterized by patchy, orange to salmon-colored or grayish plaques covered with yellowish, greasy scales. Another severe form is pityriasis amiantacea, which involves accumulation of scale around the hair shafts⁷⁰.

Folliculitis

Folliculitis is defined as inflammation of the superficial or deep portion of the hair follicle⁷¹. This manifests as inflamed papules or pustules surrounding a hair follicle and can occur anywhere on hair-bearing skin. Although there are some noninfectious cases of folliculitis, the majority involve infectious agents such as bacteria, fungi, viruses, and parasites, with bacteria being the most common cause⁷².

A subtype of folliculitis that specifically targets the scalp is called folliculitis decalvans (FD). As in the case of seborrheic dermatitis, the cause of FD remains unknown. Although Staphylococcus aureus is frequently found in cultures taken from pustules at FD sites, it is unlikely that this condition is a simple bacterial infection.

4. Nutritional Deficiencies

Deficiencies in key nutrients, particularly vitamin D, iron, and B vitamins, weaken immune function and increase susceptibility to inflammation. Ensuring adequate nutrient intake is essential for managing inflammatory hair loss, as these nutrients support immune regulation and hair follicle health.

5. Drug Toxicity and Immune Activation

Certain medications, including statins and antidepressants like bupropion, can induce inflammatory responses in some individuals. These responses may trigger hair loss or exacerbate existing inflammatory conditions. A careful review of medications is often advised to identify potential links to hair loss.

6. Blood Type

According to the GTM, blood type also impacts one’s risk of developing illnesses, which can then lead to inflammatory responses affecting the hair follicle.

In a study conducted in northern Ethiopia, the B blood group has been found to be positively associated with type II diabetes, while the O blood group was negatively associated with type II diabetes⁷³. In a separate study conducted in Turkey, type A blood was found to be the most common blood type of the rheumatic diseases. The same study also found that familial Mediterranean fever, systemic lupus erythematosus, systemic sclerosis, and Sjögren’s syndrome were more common among those with type O blood⁷⁴. Another study in Spain yielded results that suggest O negative blood to be protective regarding the risk of having multiple sclerosis, whereas RH+ plus A or B type blood had a greater risk of developing multiple sclerosis⁷⁵.

Treatment and Management Strategies

A holistic, multi-targeted approach addressing systemic inflammation and immune dysregulation is recommended for inflammatory hair loss. Treatment options include:

1. Gut Microbiome Support

Improving gut health through prebiotics and probiotics can reduce systemic inflammation, which may help mitigate hair loss. Ingredients such as hydrolyzed guar gum fiber, chicory root, and Lactobacillus acidophilus are commonly recommended to support a balanced gut microbiome⁷⁶.

2. Immune-Modulating Nutritional Support

Nutritional support with supplements such as omega-3 fatty acids, vitamin D, and B vitamins can help modulate the immune response. Omega-3, in particular, possesses anti- inflammatory properties that are beneficial for reducing systemic inflammation⁷⁷.

3. Topical Anti-Inflammatory and Antimicrobial Treatments

Essential oils with antimicrobial properties, including tea tree, rosemary, and thyme, can help maintain a balanced scalp microbiome. Topical antifungal agents, such as ketoconazole, have been effective in treating microbial infections linked to scalp inflammation⁷⁸. Rosemary extract, in particular, has shown promising results comparable to minoxidil in promoting hair growth⁷⁹.

4. Immune-Modulating Medications

For cases involving autoimmune factors, immune-modulating medications such as Janus kinase inhibitors and biologics have shown promise. However, these therapies require careful management due to potential side effects⁸⁰.

5. Scalp Hygiene and Care

Regular scalp cleansing can reduce microbial buildup and inflammation. Mild, non-irritating shampoos used daily can help maintain scalp health and reduce inflammation.

6. Alternative and Adjunctive Therapies

Supplements such as grapefruit seed extract and magnesium, as well as platelet-rich plasma (PRP) therapy, offer adjunctive support in managing inflammation and promoting hair growth.

Conclusion

This white paper highlights the role of inflammation as a central mechanism underlying various hair loss conditions. Understanding the links between immune dysregulation, gut microbiome health, microbial imbalances, and nutritional status is crucial for effective management. While individualized treatments remain essential, an integrated approach targeting inflammation at its roots offers promising avenues for improving outcomes in patients with inflammatory hair loss conditions. Further research is required to clarify the complex interactions within the immune response to develop optimized, patient-specific interventions.

Section 6: Growth Stimulants: Maximizing Benefits by Addressing Root Causes First

Growth stimulants have become an essential component in hair restoration therapy, valued for their ability to support cellular recovery, improve scalp blood flow, and extend the active growth phase of hair follicles. However, while these stimulants promote hair regrowth, they do not address the underlying causes of hair loss—typically associated with hormonal imbalances (notably DHT), nutritional deficiencies, and chronic inflammation. Without first blocking these root causes, growth stimulants often yield limited benefits and may come with side effects that further complicate treatment⁸¹.

This section explores the mechanisms of growth stimulants, the limitations of their efficacy when underlying causes are unaddressed, and how to best incorporate these stimulants for optimal results.

Overview of Growth Stimulants

Growth stimulants work by enhancing the growth potential of hair follicles. Yet, without stabilizing the primary causes of hair loss, their benefits can be minimal and short-lived, often leading to patient dissatisfaction or the need for ongoing, high-dosage applications. Prolonged use without addressing underlying issues may also exacerbate adverse effects. Therefore, it is critical to manage the root causes before introducing growth stimulants into a treatment plan.

Mechanisms and Limitations of Growth Stimulants Without Addressing Root Causes

1. Minoxidil

Minoxidil enhances blood flow and prolongs the anagen phase, leading to thicker hair strands. However, without first managing DHT, inflammation, or nutritional deficiencies, minoxidil’s effectiveness diminishes⁸².

Potential Side Effects

Patients may experience increased shedding, scalp irritation, and dermatitis, especially when used as a standalone treatment. Over time, reliance on minoxidil without underlying cause management can lead to “diminishing returns,” where the benefits plateau or regress, requiring increased dosage or continuous application.

2. Low-Level Laser Therapy (LLLT)

LLLT uses red or near-infrared light to stimulate cellular activity and improve scalp circulation. Despite its ability to boost hair density in the short term, LLLT may yield insufficient benefits if hormonal imbalances or scalp inflammation are not controlled⁸³ .

Potential Side Effects

Temporary redness and scalp discomfort may occur, particularly if the scalp is already inflamed or compromised by other underlying factors. Without addressing these factors, LLLT results may be short-term or marginal.

3. Platelet-Rich Plasma (PRP)

PRP injections promote follicle health by delivering growth factors directly to the scalp. However, in cases where DHT remains high or nutritional deficiencies are untreated, PRP’s effects are likely to be limited, leading to temporary or partial hair density improvements⁸⁴ .

Potential Side Effects

Swelling, tenderness, or bruising at injection sites are common, with results that may fail to meet expectations if underlying conditions are left unaddressed. PRP’s benefits are maximized only when administered as part of a stabilized treatment environment.

4. Exosomes

Exosome therapy introduces regenerative vesicles into the scalp to promote hair growth. Yet, without addressing inflammatory or hormonal imbalances, exosomes may provide limited and transient effects⁸⁵ .

Potential Side Effects

Scalp sensitivity and inflammation may occur if applied on an already irritated or unbalanced scalp⁸⁶ . Given the cost and experimental status of exosome therapy, its use without a comprehensive approach to hair loss may result in unsatisfactory or fleeting outcomes⁸⁷.

5. Peptides

Peptides like tripeptide complexes promote follicle activity and support hair growth but do not address the underlying causes of hair loss⁸⁸ .

Potential Side Effects

Scalp irritation or sensitization may arise, especially in patients with high DHT levels or unmanaged inflammation. Peptide treatments often require ongoing application to sustain results, and their efficacy is markedly enhanced only when root causes are controlled.

6. Microneedling

Microneedling creates micro-wounds that stimulate growth factor release. This treatment’s efficacy is enhanced when underlying inflammatory or hormonal factors are stabilized, as these factors can impede healing and follicle stimulation⁸⁹.

Potential Side Effects

Scalp discomfort, redness, and minor inflammation are common, particularly when applied to an inflamed scalp. Without underlying cause management, microneedling results may be short-lived, and patients may require more frequent treatments, increasing the risk of side effects⁹⁰.

Risks and Diminished Benefits of Using Growth Stimulants Without Managing Root Causes

When growth stimulants are used in isolation, patients often experience suboptimal benefits and are more likely to encounter side effects.

Conditions like androgenetic alopecia (AGA) are hormonally driven, and DHT-related follicle miniaturization will continue unless directly managed⁹¹. Additionally, chronic inflammation or nutrient deficiencies further compromise follicle health, limiting growth stimulants’ effectiveness. This can lead to unnecessary costs, frustration, and the potential for treatment-related complications.

Best Practices: Integrating Growth Stimulants After Blocking Root Causes

To maximize the benefits of growth stimulants and minimize side effects:

1. Block DHT and Manage Hormonal Imbalances

DHT blockers should be incorporated as a foundational treatment to reduce the risk of continued follicle miniaturization. Only after DHT levels are stabilized should growth stimulants be introduced, allowing them to work more effectively and with fewer adverse reactions.

2. Correct Nutritional Deficiencies

Addressing deficiencies in vitamin D, B12, iron, and other essential nutrients can improve follicle health⁹². Optimized nutritional status ensures that growth stimulants have a more supportive environment, enhancing their efficacy and sustainability.

3. Reduce Scalp Inflammation

Inflammatory scalp conditions can exacerbate side effects and diminish treatment results. Anti-inflammatory strategies—such as topical anti-inflammatory agents or lifestyle changes— create a more balanced scalp environment, allowing growth stimulants to deliver better and longer-lasting results.

Conclusion

Growth stimulants offer essential support for hair restoration, but their efficacy depends on an optimized scalp and systemic environment. By addressing the root causes of hair loss—hormonal imbalances, inflammation, and nutrient deficiencies—through the GTM, growth stimulants can perform optimally, delivering enhanced, sustainable results with minimal side effects. A comprehensive approach—addressing the root cause before introducing stimulants—provides the most effective path to long-term hair restoration.

Section 7: Gaps in Knowledge

There is a conflicting body of research regarding vitamin and mineral supplementation for the treatment of hair loss. Future research should examine the effects of vitamin and mineral supplementation to address nutritional factors leading to hair loss. Additionally, future studies may provide clarity on the relationship between the gut microbiome, gut dysbiosis, and hair loss by way of inflammatory response and nutrient deficiency.

With an increasing body of research suggesting that there are distinctions between FPHL and MPHL, there is a need for further research delving into the pathogenesis and etiology of FPHL. With a greater understanding of FPHL, MPHL, and their differences, more effective treatments for each condition can be developed. Historically, it has been a frequent practice that current therapies are offered as a blanket treatment rather than considering the individual patient’s needs and preferences. Treatments that cater to the patient’s individual experience with hair loss could be more effective than a general treatment that has been found to be beneficial for multiple kinds of alopecia.

Additional research regarding the previously mentioned growth stimulant is needed to fully understand their role in promoting hair growth. These therapies are relatively new yet promising, though the mechanism of action for each is not well-known at this time.

Section 8: Conclusion

The GTM presents a promising approach to addressing hair loss by offering a holistic and personalized treatment plan. Unlike conventional treatments that often take a one-size-fits-all approach, the GTM customizes treatments to the specific needs of each patient while addressing the three main factors contributing to hair loss: hormonal, nutritional, and inflammatory. While traditional treatments like finasteride and minoxidil have been widely used, they come with limitations and potential side effects. The GTM, on the other hand, integrates natural remedies and dietary supports to complement traditional treatments, providing a more comprehensive and effective solution for hair loss.

This approach underscores the importance of individualized approaches to medical care, recognizing that each patient is unique and may respond differently to treatments based on their genetic makeup, lifestyle factors, and overall health profile. As the understanding of hair loss continues to evolve, personalized approaches like the GTM may pave the way for more effective hair growth treatments in the future that lead to more efficacious treatments, reduced possibility for side effects, and greater patient satisfaction.

The main limitation of this paper is the lack of clinical research for several hair loss treatments and hair loss causes. Vitamin and mineral deficiencies, while observed in patients experiencing hair loss, have not been fully addressed as a factor in hair loss and hair growth. There exists limited research through which clinical trials investigate vitamin supplementation as a treatment option for hair loss. There has been evidence that potentially links the gut microbiome, vitamin and mineral deficiencies, and hair loss, but further research is needed to clarify this relationship. Finally, previous research has found differences in the manifestation and presentation of MPHL and FPHL, prompting some experts to consider them separate issues. Many of the leading treatments have been formulated to treat MPHL without considering that FPHL patients may need entirely different treatment options. Further research must separate MPHL and FPHL in order to develop treatments best suited for each condition.

The main objective of this paper is to detail the main pillars of the GTM and demonstrate the effectiveness of the methodology compared to conventional treatments for hair loss. Although more research is needed for several of the treatments mentioned, there is a wealth of information establishing that hair loss can be treated in a variety of ways. The GTM stays informed on the latest hair loss findings and incorporates new, promising therapies in its methodology to best serve its patients.

Contact Evolution Hair Loss Institute for more information on how to incorporate the Gaunitz Trichology Methodology and Advanced Trichology Products in your practice.

Methodology

This review of the literature on hair loss was conducted between January and November 2024 using the following biomedical databases: 1) the National Library of Medicine’s PubMed, 2) Medline, 3) CINAHL Plus, 4) Embase, and 5) Cochrane. For clinical decision-making guidelines, we consulted tools such as UpToDate.

Where appropriate, we also consulted relevant textbooks, news articles, official communications from regulatory agencies (e.g., FDA), and national and international society guidelines. Certain reports from private research institutions such as Gartner and Grand View Research may have been consulted as well.

The structured search of the literature included the following terms: “alopecia”, “hair loss”, “hair growth”, “dihydrotestosterone”, “finasteride”, “dutasteride”, “minoxidil”, “saw palmetto”, “pumpkin seed”, “rosemary”, “vitamin D”, “vitamin B”, “ferritin”, “folate”, “iron”, “zinc”, “gut microbiome”, “dysbiosis”, “drug toxicity”, “statins”, “Wellbutrin”, “bupropion”, “laser”, “plasma”, “exosomes”, “peptides”, and “microneedling”. If available, we included MeSH (medical subject headings) terms in our search.

The inclusion criteria for the articles was as follows:

1. Articles available in English.
2. Published in peer-reviewed journals.
3. Published after the year 2000, with a primary focus on articles published between 2019 and 2024.

Each article was assessed based on the relevance of the topic found in the title and the abstract. A total of 92 peer-reviewed articles were cited for this paper.

Limitations

We acknowledge certain limitations such as the relatively few data from randomized clinical trials and systematic reviews on nutritional and other interventions for hair loss.

In producing this report, we have considered the best available evidence. However, because there are certain gaps in knowledge until more information is available, certain recommendations are based on societal guidelines or expert opinions. Expert recommendations do not replace high-level evidence, particularly randomized controlled trials and systematic reviews and metanalyses. Given this limitation, the reader should exercise caution when using the information contained in this report to make clinical or business decisions.

Authors

Samuel Sarmiento, MD, MPH, MBA
Carrie Haney, MSPH
Juniper Life Sciences
San Diego, CA

References

• 1. ^Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759-3781. doi:10.1111/jocd.14537
  2. ^Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date. Drug Des Devel Ther. 2020;Volume 14:951-959. doi:10.2147/DDDT.S240615
  3. ^Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primer. 2017;3(1):17011. doi:10.1038/nrdp.2017.11
  4. ^Müller Ramos P, Melo DF, Radwanski H, De Almeida RFC, Miot HA. Female-pattern hair loss: therapeutic update. An Bras Dermatol. 2023;98(4):506-519. doi:10.1016/j.abd.2022.09.006
  5. ^Stefanicka-Wojtas D, Kurpas D. Personalised Medicine—Implementation to the Healthcare System in Europe (Focus Group Discussions). J Pers Med. 2023;13(3):380. doi:10.3390/jpm13030380
  6. ^Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002;198(1-2):89-95. doi:10.1016/S0303-7207(02)00372-6
  7. ^Dhurat R, Sharma A, Rudnicka L, et al. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Dermatol Ther. 2020;33(3). doi:10.1111/dth.13379
  8. ^Hamilton, J.B. Male hormone stimulation is prerequisite and an incitant in common baldness. Am. J. Anat., 1942;71: 451-480. https://doi.org/10.1002/aja.1000710306
  9. ^Hamilton, JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728. doi:10.1111/j.1749-6632.1951.tb31971.x
  10. ^Suchonwanit P, Iamsumang W, Leerunyakul K. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. J Dermatol Treat. 2022;33(2):643-648. doi:10.1080/09546634.2020.1782324
  11. ^Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186(4170):1213-1215. doi:10.1126/science.186.4170.1213
  12. ^Rebora A. Telogen effluvium: a comprehensive review. Clin Cosmet Investig Dermatol. 2019;Volume 12:583-590. doi:10.2147/CCID.S200471
  13. ^Yorulmaz A, Hayran Y, Ozdemir AK, et al. Telogen effluvium in daily practice: Patient characteristics, laboratory parameters, and treatment modalities of 3028 patients with telogen effluvium. J Cosmet Dermatol. 2022;21(6):2610-2617. doi:10.1111/jocd.14413
  14. ^Gupta AK, Talukder M. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative? J Cosmet Dermatol. 2022;21(5):1841-1848. doi:10.1111/jocd.14895
  15. ^Leliefeld HHJ, Debruyne FMJ, Reisman Y. The post-finasteride syndrome: possible etiological mechanisms and symptoms. Int J Impot Res. Published online September 11, 2023. doi:10.1038/s41443-023-00759-5
  16. ^Carrington AE, Maloh J, Nong Y, Agbai ON, Bodemer AA, Sivamani RK. The Gut and Skin Microbiome in Alopecia: Associations and Interventions. 2023;16(10).
  17. ^Fertig RM, Gamret AC, Darwin E, Gaudi S. Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Dermatol Online J. 2017;23(11). doi:10.5070/D32311037240
  18. ^Albasher G, Bin-Jumah M, Alfarraj S, et al. Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women. Biosci Rep. 2020;40(2):BSR20191434. doi:10.1042/BSR20191434
  19. ^Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatol Treat. 2022;33(7):2946-2962. doi:10.1080/09546634.2022.2109567
  20. ^Wall D, Meah N, Fagan N, York K, Sinclair R. Advances in hair growth. Fac Rev. 2022;11. doi:10.12703/r/11-1
  21. ^Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety.J Am Acad Dermatol. 2021;84(3):737-746. doi:10.1016/j.jaad.2020.06.1009
  22. ^Begum A, Sandhya S, Anoop Kumar N, Ali S. Evaluation of herbal hair lotion loaded with rosemary for possible hair growth in C57BL/6 mice. Adv Biomed Res. 2023;12(1):60. doi:10.4103/abr.abr_306_21
  23. ^Sudeep HV, Rashmi S, Jestin TV, Richards A, Gouthamchandra K, Shyamprasad K. Oral and Topical Administration of a Standardized Saw Palmetto Oil Reduces Hair Fall and Improves the Hair Growth in Androgenetic Alopecia Subjects – A 16-Week Randomized, Placebo- Controlled Study. Clin Cosmet Investig Dermatol. 2023;Volume 16:3251-3266. doi:10.2147/CCID.S435795
  24. ^Dhariwala MY, Ravikumar P. An overview of herbal alternatives in androgenetic alopecia. J Cosmet Dermatol. 2019;18(4):966-975. doi:10.1111/jocd.12930
  25. ^Rossi A, Mari E, Scarnò M, et al. Comparitive Effectiveness and Finasteride Vs Serenoa Repens in Male Androgenetic Alopecia: A Two-Year Study. Int J Immunopathol Pharmacol. 2012;25(4):1167-1173. doi:10.1177/039463201202500435
  26. ^Cheng Y, Chen Y, Li J, et al. Dietary β-sitosterol regulates serum lipid level and improves immune function, antioxidant status, and intestinal morphology in broilers. Poult Sci. 2020;99(3):1400-1408. doi:10.1016/j.psj.2019.10.025
  27. ^Kim KA, Lee IA, Gu W, Hyam SR, Kim DH. β-Sitosterol attenuates high-fat diet-induced intestinal inflammation in mice by inhibiting the binding of lipopolysaccharide to toll-like receptor 4 in the NF-κB pathway. Mol Nutr Food Res. 2014;58(5):963-972. doi:10.1002/mnfr.201300433
  28. ^Cho YH, Lee SY, Jeong DW, et al. Effect of Pumpkin Seed Oil on Hair Growth in Men with Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2014;2014:1-7. doi:10.1155/2014/549721
  29. ^Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatol Ther. 2019;9(1):51-70. doi:10.1007/s13555-018-0278-6
  30. ^Saini K, Mysore V. Role of vitamin D in hair loss: A short review. J Cosmet Dermatol. 2021;20(11):3407-3414. doi:10.1111/jocd.14421
  31. ^Arslan H, Gündüz Ö. Micronutrient Deficiencies and Digital Computerized Phototrichogram Analysis in Telogen Effluvium: A Retrospective Correlation Study in a Tertiary Medical Center. Dermatol Pract Concept. Published online July 31, 2023:e2023202. doi:10.5826/dpc.1303a202
  32. ^Tamer F, Yuksel M, Karabag Y. Serum ferritin and vitamin D levels should be evaluated in patients with diffuse hair loss prior to treatment. Adv Dermatol Allergol. 2020;37(3):407-411. doi:10.5114/ada.2020.96251
  33. ^Ali MS, Hafiz HSA, Ahmed NA, Galal SA. Combined microneedling with topical vitamin D3 or bimatoprost versus microneedling alone in the treatment of alopecia areata: A comparative randomized trial. J Cosmet Dermatol. 2023;22(4):1286-1296. doi:10.1111/jocd.15569
  34. ^Hayashi A, Mikami Y, Miyamoto K, et al. Intestinal Dysbiosis and Biotin Deprivation Induce Alopecia through Overgrowth of Lactobacillus murinus in Mice. Cell Rep. 2017;20(7):1513- 1524. doi:10.1016/j.celrep.2017.07.057
  35. ^Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006;54(5):824-844. doi:10.1016/j.jaad.2005.11.1104
  36. ^Cappellini MD, Comin-Colet J, De Francisco A, et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017;92(10):1068-1078. doi:10.1002/ajh.24820
  37. ^Park SY, Na SY, Kim JH, Cho S, Lee JH. Iron Plays a Certain Role in Patterned Hair Loss. J Korean Med Sci. 2013;28(6):934. doi:10.3346/jkms.2013.28.6.934
  38. ^Kil MS, Kim CW, Kim SS. Analysis of Serum Zinc and Copper Concentrations in Hair Loss. Ann Dermatol. 2013;25(4):405. doi:10.5021/ad.2013.25.4.405
  39. ^Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata. J Am Acad Dermatol. 2018;78(1):1-12. doi:10.1016/j.jaad.2017.04.1141
  40. ^Zhou C, Li X, Wang C, Zhang J. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. Clin Rev Allergy Immunol. 2021;61(3):403-423. doi:10.1007/s12016-021-08883-0
  41. ^Jung DR, Yoo HY, Kim MJ, et al. Comparative analysis of scalp and gut microbiome in androgenetic alopecia: A Korean cross-sectional study. Front Microbiol. 2022;13:1076242. doi:10.3389/fmicb.2022.1076242
  42. ^Liu Z, Liu X. Gut microbiome, metabolome and alopecia areata. Front Microbiol. 2023;14:1281660. doi:10.3389/fmicb.2023.1281660
  43. ^Freitas Gouveia M, Trüeb RM. Unsuccessful Treatment of Alopecia Areata with Simvastatin/Ezetimibe: Experience in 12 Patients. Skin Appendage Disord. 2017;3(3):156-160. doi:10.1159/000468991
  44. ^Eskeland S, Halvorsen J, Tanum L. Antidepressants have Anti-inflammatory Effects that may be Relevant to Dermatology: A Systematic Review. Acta Derm Venereol. 2017;97(8):897- 905. doi:10.2340/00015555-2702
  45. ^Etminan M, Sodhi M, Procyshyn RM, Guo M, Carleton BC. Risk of hair loss with different antidepressants: a comparative retrospective cohort study. Int Clin Psychopharmacol. 2018;33(1):44-48. doi:10.1097/YIC.0000000000000191
  46. ^Legese B, Abebe M, Fasil A. Association of ABO and Rh Blood Group Phenotypes with Type 2 Diabetes Mellitus at Felege Hiwot Comprehensive Referral Hospital Bahir Dar, Northwest Ethiopia. Schneider JG, ed. Int J Chronic Dis. 2020;2020:1-9. doi:10.1155/2020/2535843
  47. ^Cildag S, Kara Y, Senturk T. ABO blood groups and rheumatic diseases. Eur J Rheumatol. 2017;4(4):250-253. doi:10.5152/eurjrheum.2017.17044
  48. ^https://www.naaf.org/alopecia-areata/types-of-alopecia-areata
  49. ^Lopetegi I, Muñoz-Lopetegi A, Arruti M, et al. ABO blood group distributions in multiple sclerosis patients from Basque Country; O – as a protective factor. Mult Scler J – Exp Transl Clin. 2019;5(4):205521731988895. doi:10.1177/2055217319888957
  50. ^Kost Y, Muskat A, Mhaimeed N, Nazarian RS, Kobets K. Exosome therapy in hair regeneration: A literature review of the evidence, challenges, and future opportunities. J Cosmet Dermatol. 2022;21(8):3226-3231. doi:10.1111/jocd.15008
  51. ^Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5- Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Ann Dermatol. 2016;28(4):438. doi:10.5021/ad.2016.28.4.438
  52. ^Patel S, Sharma V, Chauhan NS, Thakur M, Dixit VK. Hair Growth: Focus on Herbal Therapeutic Agent. Curr Drug Discov Technol. 2015;12(1):21-42. doi:10.2174/1570163812666150610115055
  53. ^Goluch-Koniuszy Z. Nutrition of women with hair loss problem during the period of menopause. Menopause Review/Przegląd Menopauzalny. 2016;15(1):56-61.doi:10.5114/pm.2016.58776
  54. ^Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol. 2002;27(5):396-404. doi:10.1046/j.1365-2230.2002.01076.x
  55. ^Rajendrasingh JR. Role of non-androgenic factors in hair loss and hair regrowth. J Cosmo Trichol. 2017;3:118. https://doi.org/10.4172/2471-9323.1000118
  56. ^Sakkas H, Bozidis P, Touzios C, Kolios D, Athanasiou G, Athanasopoulou E, Gerou I, Gartzonika C. Nutritional Status and the Influence of the Vegan Diet on the Gut Microbiota and Human Health. Medicina. 2020; 56(2):88.https://doi.org/10.3390/medicina56020088
  57. ^Ma YQ, Sun Z, Li YM, Xu H. Oxidative stress and alopecia areata. Front Med (Lausanne). 2023;10:1181572. Published 2023 Jun 15. doi:10.3389/fmed.2023.1181572
  58. ^Zari J, Abdolmajid F, Masood M, Vahid M, Yalda N. Evaluation of the relationship between androgenetic alopecia and demodex infestation. Indian J Dermatol. 2008;53(2):64-67. doi:10.4103/0019-5154.41647
  59. ^Sánchez-Pellicer P, Navarro-Moratalla L, Núñez-Delegido E, Agüera-Santos J, Navarro- López V. How Our Microbiome Influences the Pathogenesis of Alopecia Areata. Genes (Basel). 2022;13(10):1860. Published 2022 Oct 14. doi:10.3390/genes13101860
  60. ^Damgaard, M and Treebak, J. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci. Adv. 9, eadi4862 (2023).
  61. ^Starace M, Orlando G, Alessandrini A, Piraccini BM. Female Androgenetic Alopecia: An Update on Diagnosis and Management. Am J Clin Dermatol. 2020;21(1):69-84. doi:10.1007/s40257-019-00479-x
  62. ^Owecka B, Tomaszewska A, Dobrzeniecki K, Owecki M. The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Biomedicines. 2024;12(3):513. Published 2024 Feb 24. doi:10.3390/biomedicines12030513
  63. ^Maria Borrás J, Piqué N, Nieto C, González J. Efficacy and safety of a dietary supplement containing a lipid co-extract from Serenoa repens and Pygeum africanum for the treatment of androgenetic alopecia (AGA) in women. Results of a randomized, double-blind, placebo- controlled clinical trial. Más dermatología. 2016;(25):5-14. doi:https://doi.org/10.5538/1887-5181.2016.25.5
  64. ^Pekmezci E, Dündar C, Türkoğlu M. A proprietary herbal extract against hair loss in androgenetic alopecia and telogen effluvium: a placebo-controlled, single-blind, clinical- instrumental study. Acta Dermatovenerologica Alpina Pannonica et Adriatica. 2018;27(2). doi:https://doi.org/10.15570/actaapa.2018.13
  65. ^Fischer T, Hänggi G, Innocenti M, Elsner P, Trüeb R. Topical Melatonin for Treatment of Androgenetic Alopecia. International Journal of Trichology. 2012;4(4):236. doi:https://doi.org/10.4103/0974-7753.111199
  66. ^Larrondo J, McMichael AJ. Traction Alopecia. JAMA Dermatol. 2023;159(6):676.doi:10.1001/jamadermatol.2022.6298
  67. ^Saleh D, Nassereddin A, Saleh HM, Cook C. Anagen Effluvium. In: StatPearls. Treasure Island (FL): StatPearls Publishing; April 30, 2024.
  68. ^Filbrandt R, Rufaut N, Jones L, Sinclair R. Primary cicatricial alopecia: diagnosis and treatment. CMAJ. 2013;185(18):1579-1585. doi:10.1503/cmaj.111570
  69. ^Kerkemeyer KLS, Eisman S, Bhoyrul B, Pinczewski J, Sinclair RD. Frontal fibrosing alopecia. Clin Dermatol. 2021;39(2):183-193. doi:10.1016/j.clindermatol.2020.10.007
  70. ^Bolduc C, Sperling LC, Shapiro J. Primary cicatricial alopecia: Other lymphocytic primary cicatricial alopecias and neutrophilic and mixed primary cicatricial alopecias. J Am Acad Dermatol. 2016;75(6):1101-1117. doi:10.1016/j.jaad.2015.01.056
  71. ^Silva GB, Ciccolini K, Donati A, Hurk CVD. Scalp cooling to prevent chemotherapy-induced alopecia. An Bras Dermatol. 2020;95(5):631-637. doi:10.1016/j.abd.2020.03.005
  72. ^Galadari H, Shivakumar S, Lotti T, et al. Low-level laser therapy and narrative review of other treatment modalities in androgenetic alopecia. Lasers Med Sci. 2020;35(6):1239- 1244. doi:10.1007/s10103-020-02994-4
  73. ^Pillai JK, Mysore V. Role of Low-Level Light Therapy (LLLT) in Androgenetic Alopecia. J Cutan Aesthet Surg. 2021;14(4):385-391. doi:10.4103/JCAS.JCAS_218_20
  74. ^Gentile P, Garcovich S. The Effectiveness of Low-Level Light/Laser Therapy on Hair Loss.Facial Plast Surg Aesthet Med. 2024;26(2):228-235. doi:10.1089/fpsam.2021.0151
  75. ^Faghihi G, Nabavinejad S, Mokhtari F, Fatemi Naeini F, Iraji F. Microneedling in androgenetic alopecia; comparing two different depths of microneedles. J Cosmet Dermatol. 2021;20(4):1241–1247
  76. ^Gupta AK, Quinlan EM, Venkataraman M, Bamimore MA. Microneedling for Hair Loss. J Cosmet Dermatol. 2022;21(1):108.
  77. ^Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015.
  78. ^Hald M, Arendrup MC, Svejgaard EL, Lindskov R, Foged EK, Saunte DM. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. Acta Derm Venereol. 2015 Jan;95(1):12-9.
  79. ^Jiang J, Tsuboi R, Kojima Y, Ogawa H. Topical application of ketoconazole stimulates hair growth in C3H/HeN mice. J Dermatol. 2005;32(4):243-247. doi:10.1111/j.1346- 8138.2005.tb00756.x
  80. ^Green CA, Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol. 1987;116(2):217-221. doi:10.1111/j.1365-2133.1987.tb05815.x
  81. ^English RS Jr, Ruiz S, DoAmaral P. Microneedling and Its Use in Hair Loss Disorders: A Systematic Review. Dermatol Ther (Heidelb). 2022;12(1):41. Epub 2021 Dec 1.
  82. ^Elewski BE. Clinical diagnosis of common scalp disorders. J Investig Dermatol Symp Proc. 2005;10(3):190-193. doi:10.1111/j.1087-0024.2005.10103.x
  83. ^Tao R, Li R, Wang R. Skin microbiome alterations in seborrheic dermatitis and dandruff: A systematic review. Exp Dermatol. 2021;30(10):1546-1553. doi:10.1111/exd.14450
  84. ^Schwartz JR, Messenger AG, Tosti A, et al. A comprehensive pathophysiology of dandruff and seborrheic dermatitis – towards a more precise definition of scalp health. Acta Derm Venereol. 2013;93(2):131-137. doi:10.2340/00015555-1382
  85. ^Limbu SL, Purba TS, Harries M, et al. A folliculocentric perspective of dandruff pathogenesis: Could a troublesome condition be caused by changes to a natural secretory mechanism?. Bioessays. 2021;43(10):e2100005.doi:10.1002/bies.202100005
  86. ^Borda LJ, Wikramanayake TC. Seborrheic Dermatitis and Dandruff: A Comprehensive Review. J Clin Investig Dermatol. 2015;3(2):10.13188/2373-1044.1000019. doi:10.13188/2373-1044.1000019
  87. ^Luelmo-Aguilar J, Santandreu MS. Folliculitis: recognition and management. Am J Clin Dermatol. 2004;5(5):301-10.
  88. ^Laureano AC, Schwartz RA, Cohen PJ. Facial bacterial infections: folliculitis. Clin Dermatol.2014 Nov-Dec;32(6):711-4.
  89. ^Matard B, Donay JL, Resche-Rigon M, et al. Folliculitis decalvans is characterized by a persistent, abnormal subepidermal microbiota. Exp Dermatol. 2020;29(3):295.
  90. ^Mustarichie R, Rostinawati T, Pitaloka DAE, Saptarini NM, Iskandar Y. Herbal Therapy for the Treatment of Seborrhea Dermatitis. Clin Cosmet Investig Dermatol. 2022;15:2391- 2405. Published 2022 Nov 7. doi:10.2147/CCID.S376700
  91. ^Dinkins J, Iwuala C, Akintilo L, et al. Commonly used hair oils in the Black community: a narrative review in their use to treat androgenetic alopecia. Int J Dermatol. 2023;62(8):980- 985. doi:10.1111/ijd.16657
  92. ^Bungau AF, Radu AF, Bungau SG, et al. Emerging Insights into the Applicability of Essential Oils in the Management of Acne Vulgaris. Molecules. 2023;28(17):6395. Published 2023 Sep 1. doi:10.3390/molecules28176395

About the Author

Dr. Samuel Sarmiento Author

Dr. Samuel Sarmiento is a physician with a rich background in clinical medicine, public health, and research. He completed his surgical internship at the Mayo Clinic, where he gained invaluable experience in one of the world's most renowned healthcare institutions. Recognizing the need to broaden his expertise beyond clinical practice, he pursued dual master’s degrees in Public Health and Business Administration at Johns Hopkins University, followed by a postdoctoral fellowship in clinical outcomes research within the Department of Plastic Surgery. View Full Profile